MediWound Ltd. (MDWD) Stake Maintained by California Public Employees Retirement System
California Public Employees Retirement System continued to hold its position in shares of MediWound Ltd. (NASDAQ:MDWD) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 199,900 shares of the biopharmaceutical company’s stock at the end of the second quarter. California Public Employees Retirement System owned 0.91% of MediWound worth $1,567,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of MDWD. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of MediWound during the second quarter worth about $13,302,000. Renaissance Technologies LLC raised its position in shares of MediWound by 19.4% in the first quarter. Renaissance Technologies LLC now owns 49,800 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 8,100 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in shares of MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock valued at $8,431,000 after buying an additional 100,723 shares during the last quarter. Institutional investors and hedge funds own 26.48% of the company’s stock.
Shares of MediWound Ltd. (NASDAQ:MDWD) traded down 0.13% during mid-day trading on Monday, hitting $7.45. 1,309 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $7.71 and a 200-day moving average price of $7.79. The stock’s market cap is $162.78 million. MediWound Ltd. has a 1-year low of $5.66 and a 1-year high of $10.47.
MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.11. The firm earned $3.36 million during the quarter, compared to the consensus estimate of $0.45 million. MediWound had a negative net margin of 2,332.07% and a negative return on equity of 103.14%. The company’s revenue for the quarter was up 115.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.19) earnings per share. Equities research analysts anticipate that MediWound Ltd. will post ($1.02) EPS for the current fiscal year.
MDWD has been the topic of several recent analyst reports. Jefferies Group lowered their target price on shares of MediWound from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, July 29th. Zacks Investment Research upgraded shares of MediWound from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a research report on Tuesday, July 12th. Finally, Wells Fargo & Co. initiated coverage on shares of MediWound in a research report on Wednesday, August 17th. They set an “outperform” rating and a $14.00 target price on the stock. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $13.63.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediWound Ltd. (NASDAQ:MDWD).
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.